ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
0,00%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,775
0,17%
Bitcoin
59 386,07
0,45%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Talaris Therapeutics Inc (TALS)

  7. Talaris Therapeutics Inc (TALS) Actualités

TALS Talaris Therapeutics Inc

2,72
0,00 (0,00%)
02 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Talaris Therapeutics Inc TALS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 2,72 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,72 2,72
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
19/4/202422:05EDGAR2Form ARS - Annual Report to Security Holders
19/4/202422:04EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
19/4/202422:02EDGAR2Form DEF 14A - Other definitive proxy statements
19/3/202422:10EDGAR2Form S-8 - Securities to be offered to employees in employee..
19/3/202422:02EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
19/3/202412:09EDGAR2Form 8-K - Current report
21/11/202300:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202300:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/11/202322:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
30/10/202321:15EDGAR2Form SC 13D/A - General statement of acquisition of..
27/10/202323:17EDGAR2Form 8-K - Current report
27/10/202322:02EDGAR2Form SC 13G - Statement of acquisition of beneficial..
26/10/202323:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202322:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/10/202303:23EDGAR2Form S-8 - Securities to be offered to employees in employee..
17/10/202323:47GLOBETalaris Therapeutics Announces Stockholder Approval of..
10/10/202322:32EDGAR2Form 425 - Prospectuses and communications, business..
10/10/202322:30EDGAR2Form 8-K/A - Current report: [Amend]
07/10/202302:01DJNStocks to Watch: Shift Technologies, Talaris Therapeutics,..
06/10/202323:30EDGAR2Form 8-K - Current report
06/10/202323:27EDGAR2Form 425 - Prospectuses and communications, business..
06/10/202323:26EDGAR2Form 8-K - Current report
06/10/202323:09GLOBETalaris Therapeutics Declares Special Dividend In Connection..
04/10/202314:30GLOBENew York Blood Center Enterprises Acquires Commercial-Scale..
26/9/202314:24EDGAR2Form 425 - Prospectuses and communications, business..
26/9/202314:21EDGAR2Form 8-K - Current report
15/9/202312:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/9/202322:28EDGAR2Form S-4/A - Registration of securities, business..
13/9/202315:14EDGAR2Form 425 - Prospectuses and communications, business..
13/9/202315:13EDGAR2Form 8-K - Current report
11/9/202322:47EDGAR2Form S-4/A - Registration of securities, business..
28/8/202313:38EDGAR2Form 425 - Prospectuses and communications, business..
25/8/202322:34EDGAR2Form S-4/A - Registration of securities, business..
14/8/202313:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
22/6/202313:30GLOBETalaris Therapeutics and Tourmaline Bio Announce Merger..
26/5/202313:00GLOBETalaris Therapeutics Announces Leadership Transition

Dernières Valeurs Consultées

NASDAQ
TALS
Talaris Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés